Nature Cancer

Article	Citations
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling	327
The impact of the COVID-19 pandemic on cancer care	321
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis	271
Pan-cancer image-based detection of clinically actionable genetic alterations	270
Circulating tumor DNA and liquid biopsy in oncology	252
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab	197
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer	187
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer	174
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer	173
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma	169
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer	168
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer	141
Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity	137
A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies	137
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	130
Overcoming therapy resistance in EGFR-mutant lung cancer	126
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	125
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer	122
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome	119
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy	118
The metabolic landscape of RAS-driven cancers from biology to therapy	116
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	115
L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer	111
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation	111
Fatty acid synthesis is required for breast cancer brain metastasis	107

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	106
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells	105
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma	103
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells	99
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	98
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	97
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	92
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	91
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity	90
Cancer vaccines: the next immunotherapy frontier	89
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	89
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort	89
The immuno-oncological challenge of COVID-19	88
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	88
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	87
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity	87
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	86
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	82
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia	80
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	78
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ	78
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes	78
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment	78
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors	77
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer	77
Applications of organoids for cancer biology and precision medicine	77
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	73
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	73
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer	73
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	72
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	72
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	71
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy	70
Cancer-associated fibroblasts in the single-cell era	69
PAK4 inhibition improves PD-1 blockade immunotherapy	68
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	67
The T cell differentiation landscape is shaped by tumour mutations in lung cancer	66
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	65
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	64
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	63
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer	63
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	62
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis	60
Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis	59
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	59
Crowdsourcing a crisis response for COVID-19 in oncology	58
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	58
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	57
Translational advances in pancreatic ductal adenocarcinoma therapy	56
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	55

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	55
Emerging strategies for treating metastasis	55
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	55
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	54
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	53
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	53
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	52
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade	52
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	52
Targeting public neoantigens for cancer immunotherapy	52
c-Rel is a myeloid checkpoint for cancer immunotherapy	51
A bright future for KRAS inhibitors	50
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	49
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response	46
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	46
The global challenge of cancer	46
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision	45
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer	44
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	44
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	44
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	44
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	43
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer	42
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	42
Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer	41
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	40
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	40
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer	39
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia	39
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	39
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	39
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	38
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance	38
Engineering-enhanced CAR T cells for improved cancer therapy	38
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression	38
The present and future of PI3K inhibitors for cancer therapy	38
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	37
Dysregulation and therapeutic targeting of RNA splicing in cancer	37
Intratumor heterogeneity reflects clinical disease course	37
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	37
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	36
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer	36
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	35
Accelerating precision medicine in metastatic prostate cancer	35
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1	35
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	35
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity	35
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	34
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome	33
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma	33
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors	32
Rethinking cancer clinical trials for COVID-19 and beyond	32
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors	31
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	31
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase	31
Bystander T cells in cancer immunology and therapy	30
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	30
The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer	30
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	30
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	29
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia	29
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response	28
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis	28
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing	27
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	27
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy	27
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia	27
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	27
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	27
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia	27
The cGAS–STING pathway and cancer	27
Illuminating the noncoding genome in cancer	26
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders	26
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells	26
Zeb2 drives invasive and microbiota-dependent colon carcinoma	25
Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs	25
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma	25
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	25
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	25
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response	25

Deep learning links histology, molecular signatures and prognosis in cancer

25